China would receive cut-price supplies of GlaxoSmithKline’s new HIV drug Tivicay, after Shanghai-based Desano Pharmaceuticals became an additional manufacturer of the medicine’s active ingredient under an agreement.
Advertisement
The partnership marks an important step for GSK in improving its relations with China after the company in September 2014 was fined about $480m for bribing Chinese doctors.
At the amount of time, GSK swore to me enhance admittance to its treatments in the nation by increasing hometown creation and taking in adjustable values. ViiV spokesman, however, told that the negotiations made with the Desano existed this commitment.
Under the agreement, Desano Pharmaceuticals will manufacture the active pharmaceutical ingredient (API) of dolutegravir to feed in to the the supply chain of ViiV Healthcare, a GlaxoSmithKline and Pfizer company.
ViiV said that the move would permit it to offer a competitive supply of finished products, without determining the scale of price markdown.
“This manufacturing agreement with Desano for dolutegravir is a significant achievement to facilitate access to our medicines”, said ViiV chief executive officer Dominique Limet. ViiV and Desano are also looking into the possibility for the future manufacture of finished product, as well as fixed dose combinations dolutegravir with APIs.
Advertisement
Dolutegravir is an integrase strand transfer inhibitor (INSTI) for use in combination with other antiretroviral agents for the treatment of HIV.
